Conforma Therapeutics Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$225M
Conforma Therapeutics General Information
Description
Developer of drugs for the treatment of cancer. The company develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. It offers the HSP90 product, CNF1010 which is used for the treatment of cancer.
Contact Information
Website
www.conformacorp.comCorporate Office
- 9393 Towne Centre Drive
- Suite 240
- San Diego, CA 92121
- United States
Corporate Office
- 9393 Towne Centre Drive
- Suite 240
- San Diego, CA 92121
- United States
Conforma Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 03-May-2006 | $225M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series C) | 01-Apr-2005 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 11-Sep-2003 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 07-May-2001 | $15M | $15M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 01-Apr-2000 | Completed | Startup |
Conforma Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A1 | 2,722,222 | $0.001000 | $0.04 | $0.51 | $0.51 | 1x | $0.51 | 2.18% |
| Series A | 833,333 | $0.001000 | $0.02 | $0.3 | $0.3 | 1x | $0.3 | 0.67% |
Conforma Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Conforma Therapeutics Patents
Conforma Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2012791-A2 | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors | Inactive | 07-Feb-2006 | ||
| EP-2012791-A4 | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors | Inactive | 07-Feb-2006 | ||
| US-20070253896-A1 | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors | Inactive | 07-Feb-2006 | ||
| WO-2007092496-A2 | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors | Inactive | 07-Feb-2006 | ||
| WO-2007092496-A3 | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors | Inactive | 07-Feb-2006 | C07D487/04 |
Conforma Therapeutics Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Domain Associates | Venture Capital | Minority | ||
| Forward Ventures | Venture Capital | Minority | ||
| IngleWood Ventures | Venture Capital | Minority | ||
| Lilly Ventures | Corporate Venture Capital | Minority | ||
| Lombard Odier | Asset Manager | Minority |
Conforma Therapeutics FAQs
-
When was Conforma Therapeutics founded?
Conforma Therapeutics was founded in 1999.
-
Where is Conforma Therapeutics headquartered?
Conforma Therapeutics is headquartered in San Diego, CA.
-
What industry is Conforma Therapeutics in?
Conforma Therapeutics’s primary industry is Drug Discovery.
-
Is Conforma Therapeutics a private or public company?
Conforma Therapeutics is a Private company.
-
What is the current valuation of Conforma Therapeutics?
The current valuation of Conforma Therapeutics is .
-
What is Conforma Therapeutics’s current revenue?
The current revenue for Conforma Therapeutics is .
-
How much funding has Conforma Therapeutics raised over time?
Conforma Therapeutics has raised $66.3M.
-
Who are Conforma Therapeutics’s investors?
Domain Associates, Forward Ventures, IngleWood Ventures, Lilly Ventures, and Lombard Odier are 5 of 12 investors who have invested in Conforma Therapeutics.
-
When was Conforma Therapeutics acquired?
Conforma Therapeutics was acquired on 03-May-2006.
-
Who acquired Conforma Therapeutics?
Conforma Therapeutics was acquired by Biogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
